Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

2026-02-24 - 14:23

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today positive additional data from a Phase 3 study of paridiprubart. Read More